Last week, the company held a grand opening ceremony for a new $4.3 million (€4 million) R&D facility in Blackrock, Dublin. BD also announced an additional $32.1 million (€30 million) investment to expand its Enniscorthy, Wexford manufacturing facility.
According to a news release, the two investments should create more than 85 new jobs in Ireland.
BD plans for its new 10,600-square-foot, purpose-built R&D facility in Blackrock to house 35 high-tech workers. It complements the company’s existing Limerick R&D facility, which employs more than 300 people.
The Blackrock facility’s focus centers around the commercialization of BD’s first on-body injector device, the Evolve. It also serves as the regional base of operations for sales, technical service and corporate functional support teams.
BD plans for its new Enniscorthy investment to expand the manufacturing facility and create approximately 85 new jobs. The 40,000-square-foot expansion houses operations to manufacture a new medical technology from its peripheral intervention unit.
Michael Lohan, CEO of IDA Ireland — the country’s foreign direct investment arm — issued a message of support to BD. He noted the company’s more than 50-year presence in Ireland, saying the latest investment underscores the strategic importance of BD’s global operations.
“BD first established operations in Ireland in 1964, and since then has grown to four locations that employ more than 1,100 people across the country,” said Roland Goette, BD president of EMEA. “Ireland has proven to be a smart place to invest in both R&D, as well as manufacturing operations, and our new R&D center in Blackrock and €30 million investment in Enniscorthy are proof of BD’s long-term commitment to Ireland.
“We look forward to continuing our long tradition of high-tech medical device innovation and manufacturing here.”
